Lantern Pharma Cuts Costs 19%, Posts $17.1M Net Loss and Secures FDA IND
Lantern Pharma cut operating expenses by 19% year-over-year yet recorded a $17.1 million net loss for 2025 and warned of substantial funding needs. It secured FDA IND clearance for its pediatric CNS cancer program, dosed over 100 patients, and saw an 86% clinical benefit rate in its LP-300 trial.
1. Expense Reduction and Financial Results
Lantern Pharma achieved a 19% reduction in total operating expenses for 2025 through disciplined execution but reported a $17.1 million net loss for the full year. Management indicated it will need to raise substantial additional capital in the near term to continue advancing its pipeline.
2. Regulatory Milestone and Clinical Dosing
The company received FDA IND clearance for its pediatric CNS cancer program, marking a major regulatory achievement. To date, over 100 patients have been dosed across its AI-driven pipeline, underscoring the clinical translation of its drug candidates.
3. LP-300 Trial Data
The LP-300 HARMONIC trial, focused on never-smoker non-small cell lung cancer patients post-TKI therapy, demonstrated an 86% clinical benefit rate and a 43% objective response rate. This program targets a market opportunity exceeding $4 billion annually for this patient segment.
4. LP-184 Phase 1 Progress
In the LP-184 Phase 1 trial, Lantern Pharma achieved a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating its synthetic lethal approach. The study established a recommended Phase 2 dose and showed notable tumor reductions in patients with DNA damage repair mutations.